Foundation Medicine Acquires Lexent Bio, Inc.
June 13, 2020
Foundation Medicine has completed the acquisition of Lexent Bio, Inc., a California-based precision oncology company developing multiomics liquid biopsy platforms. The deal will accelerate Foundation Medicine's liquid biopsy research and development—incorporating low-pass WGS and methylation analysis into new assays—to expand diagnostic capabilities and support therapeutic development and earlier-stage patient monitoring.
- Buyers
- Foundation Medicine, Inc.
- Targets
- Lexent Bio, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Fulgent Genetics Acquires Fulgent Pharma
November 7, 2022
Biotechnology
Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.
-
Blueprint Medicines Acquires Lengo Therapeutics
November 29, 2021
Biotechnology
Blueprint Medicines has entered a definitive agreement to acquire privately held precision oncology company Lengo Therapeutics for $250 million in cash plus up to $215 million in regulatory- and sales-based milestones. The deal adds Lengo’s lead oral EGFR exon 20 insertion candidate LNG-451 and other preclinical precision oncology programs to Blueprint’s lung cancer portfolio, expanding its capability in brain-penetrant EGFR inhibitors.
-
Alexion (AstraZeneca Rare Disease) Acquires LogicBio Therapeutics
November 16, 2022
Biotechnology
Alexion, AstraZeneca Rare Disease, has completed its acquisition of LogicBio Therapeutics, Inc. through a tender offer and merger, making LogicBio a wholly owned subsidiary. The deal is intended to accelerate Alexion's growth in genomic medicines by adding LogicBio's genomic medicine technology and rare disease R&D expertise; LogicBio's CEO Frederic Chereau will join Alexion as SVP, Strategy and Business Development.
-
Agilent Technologies Acquires Avida Biomed
January 4, 2023
Biotechnology
Agilent Technologies has acquired Avida Biomed, an early-stage developer of high-performance NGS target enrichment workflows for cancer research. The acquisition augments Agilent's SureSelect portfolio and expands its capabilities into high-growth clinical research and diagnostics markets by adding Avida's chemistries and automatable assays compatible with Agilent platforms.
-
Lantheus Acquires Life Molecular Imaging from Life Healthcare
July 22, 2025
Healthcare Services
Lantheus Holdings, Inc. completed the acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd., gaining the Neuraceq (florbetaben F18) commercial product, expanded Alzheimer’s radiodiagnostic infrastructure, and additional R&D capabilities. As part of the transaction, Dr. Ludger Dinkelborg (formerly CEO of Life Molecular) will join Lantheus as Head of Research & Development, reporting to the CEO.
-
Sonde Health Acquires NeuroLex Laboratories
August 25, 2020
Healthcare Services
Sonde Health has acquired NeuroLex Laboratories, bringing NeuroLex's web-based voice survey platform, SurveyLex, and its biobank into Sonde's vocal biomarker technology suite. The deal combines NeuroLex's dataset and web capabilities with Sonde's mobile and voice-assistant platforms to expand research, data assets, and cross-platform voice-enabled health detection and monitoring.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.